Evidence map›Paper›PMID 38038626›Full record

ArticleHuman vaccines & immunotherapeutics2023

Prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Chinese girls and women aged 9 to 45 years, 2018-2020.

Qianhui Wu, Mengcen Qian, Sarah Welby, Adrienne Guignard, Dominique Rosillon, Kusuma Gopala, Yuan Xu, Keruo Liu, Yunkun He, Ning Jiang and 12 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Article
  5. Review
  6. Human papillomavirus infection and screening strategies.World journal of clinical oncology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 9 institutions in 5 countries.

Qianhui WuKey Laboratory of Public Health Safety, Ministry of Education, Fudan University, Shanghai, China.
Mengcen QianKey Laboratory of Public Health Safety, Ministry of Education, Fudan University, Shanghai, China.
Sarah WelbyGSK, Wavre, Belgium.
Adrienne GuignardGSK, Wavre, Belgium.
Dominique RosillonGSK, Wavre, Belgium.
Kusuma GopalaGSK, Bangalore, India.
Yuan XuGSK, Wuhan, China.
Keruo LiuGSK, Shanghai, China.
Yunkun HeGSK, Shanghai, China.
Ning JiangGSK, Shanghai, China.
Qin TanShunde District Center for Disease Control and Prevention, Guangdong, China.
Jiamin XieShunde District Center for Disease Control and Prevention, Guangdong, China.
Taoying ZhuWuhou District Center for Disease Control and Prevention, Sichuan, China.
Qizhang WangPudong New Area Center for Disease Control and Prevention, Shanghai, China.
Yingzi PanWujin District Center for Disease Control and Prevention, Jiangsu, China.
Ruikun ZengLonggang District Center for Disease Control and Prevention, Guangdong, China.
Jie YangLuohu District Center for Disease Control and Prevention, Guangdong, China.
Xiaoqian ZhaoTaocheng District Center for Disease Control and Prevention, Hebei, China.
Man ZhouXicheng District Center for Disease Control and Prevention, Beijing, China.
Adoración Navarro-TornéGSK, Wavre, Belgium.
Hongjie YuKey Laboratory of Public Health Safety, Ministry of Education, Fudan University, Shanghai, China.ORCID 0000-0002-6335-5648
Dorota BorysGSK, Wavre, Belgium.
GlaxoSmithKline (Belgium) · BEGlaxoSmithKline (China) · CNTaiwan Centers for Disease Control · TWFudan University · CNGlaxoSmithKline (India) · INNanjing Municipal Center for Disease Control And Prevention · CNShenzhen Center for Disease Control and Prevention · CNSichuan Center for Disease Control and Prevention · CNXian Center for Disease Control and Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following the approval of

Indexed as

Papillomavirus InfectionsPapillomavirus VaccinesUterine Cervical NeoplasmsAdjuvants, ImmunologicAdolescentAdultChildEast Asian PeopleFemaleHuman papillomavirus 16Human Papillomavirus VirusesHumansMiddle AgedPregnancyProduct Surveillance, PostmarketingProspective StudiesAdjuvants, ImmunologicPapillomavirus VaccinesChinaHPV-16/18 AS04-adjuvanted vaccinehuman papillomaviruspost-marketingpregnancysafety

Identifiers

PMID38038626
PMCPMC10732673
OpenAlexW4389222914

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.